Abstract
Cutaneous squamous cell carcinoma (CSCC) is one of the most common cancers worldwide, requiring effective therapeutic interventions. Retinoids are important chemopreventive and therapeutic agents for a variety of human cancers including CSCC. In this study we synthesized a novel retinoic derivative N-(4-ethoxycarbonylphenyl) isoretinamide (ECPIRM) and evaluated its biological activities and possible mechanisms in human cutaneous squamous cell lines. ECPIRM had better inhibitory effect on the proliferation of squamous carcinoma cells SCL-1 and colo-16, compared with All-trans retinoic acid and 13-cis retinoic acid. ECPIRM had less toxicity to normal keratinocyte cell line HaCaT. Mechanistically, ECPIRM induced G1 cell cycle arrest in SCL-1 cells, via the downregulation of CDK2, CDK4, cycling D1 and cyclin E expression and upregulation of p21. In addition, these effects were at least partially due to the inhibition of JNK/ ERK-AP-1 signaling pathway by ECPIRM. Importantly, these effects of ECPIRM are independent of the classical retinoid receptor pathway, suggesting that the novel compound will have less side-effects in chemotherapy. These findings demonstrate that ECPIRM is a potential inhibitor of MPAK-AP-1 pathway, and is a potential therapeutic agent against CSCC.
Keywords: AP-1, cell cycle arrest, cutaneous squamous cell carcinoma, ECPIRM, MAPK, N-(4-ethoxycarbonylphenyl) isoretinamide.
Anti-Cancer Agents in Medicinal Chemistry
Title:Synthesis and characterization of a new retinoic acid ECPIRM as potential chemotherapeutic agent for human cutaneous squamous carcinoma
Volume: 15 Issue: 9
Author(s): Mengli Zhang, Yue Tao, Pengcheng Ma, Dechuan Wang, Chundi He, Yuping Cao, Jun Wei, Lingjun Li and Lei Tao
Affiliation:
Keywords: AP-1, cell cycle arrest, cutaneous squamous cell carcinoma, ECPIRM, MAPK, N-(4-ethoxycarbonylphenyl) isoretinamide.
Abstract: Cutaneous squamous cell carcinoma (CSCC) is one of the most common cancers worldwide, requiring effective therapeutic interventions. Retinoids are important chemopreventive and therapeutic agents for a variety of human cancers including CSCC. In this study we synthesized a novel retinoic derivative N-(4-ethoxycarbonylphenyl) isoretinamide (ECPIRM) and evaluated its biological activities and possible mechanisms in human cutaneous squamous cell lines. ECPIRM had better inhibitory effect on the proliferation of squamous carcinoma cells SCL-1 and colo-16, compared with All-trans retinoic acid and 13-cis retinoic acid. ECPIRM had less toxicity to normal keratinocyte cell line HaCaT. Mechanistically, ECPIRM induced G1 cell cycle arrest in SCL-1 cells, via the downregulation of CDK2, CDK4, cycling D1 and cyclin E expression and upregulation of p21. In addition, these effects were at least partially due to the inhibition of JNK/ ERK-AP-1 signaling pathway by ECPIRM. Importantly, these effects of ECPIRM are independent of the classical retinoid receptor pathway, suggesting that the novel compound will have less side-effects in chemotherapy. These findings demonstrate that ECPIRM is a potential inhibitor of MPAK-AP-1 pathway, and is a potential therapeutic agent against CSCC.
Export Options
About this article
Cite this article as:
Zhang Mengli, Tao Yue, Ma Pengcheng, Wang Dechuan, He Chundi, Cao Yuping, Wei Jun, Li Lingjun and Tao Lei, Synthesis and characterization of a new retinoic acid ECPIRM as potential chemotherapeutic agent for human cutaneous squamous carcinoma , Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (9) . https://dx.doi.org/10.2174/1871520615666150520142719
DOI https://dx.doi.org/10.2174/1871520615666150520142719 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Advances in Nanomedicines and Targeted Therapies for Colorectal Cancer
Colorectal cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in treatment strategies. Conventional therapies often face limitations such as systemic toxicity, drug resistance, and suboptimal targeting. The advent of nanomedicines and innovative drug delivery systems offers new hope for overcoming these challenges and ...read more
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes that aid in stabilizing chromosomal makeup. The resynthesis of telomeres is supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no telomerase activity in human somatic cells, but the stem cells and germ cells undergo ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel non-invasive Adjunctive Techniques for Early Oral Cancer Diagnosis and Oral Lesions Examination
Current Pharmaceutical Design Viral Vectors for Cancer Gene Therapy: Viral Dissemination and Tumor Targeting
Current Gene Therapy Identifying Molecular Biomarker for the Lung Squamous Cell Carcinoma by Integrating Multifactorial Data
Current Bioinformatics Erythropoietin: New Approaches to Improved Molecular Designs and Therapeutic Alternatives
Current Pharmaceutical Design Topical Delivery of Drugs for the Effective Treatment of Fungal Infections of Skin
Current Pharmaceutical Design Current Status of Therapeutic Targeting of Developmental Signalling Pathways in Oncology
Current Pharmaceutical Biotechnology High Expression of Human Leukocyte Antigen-G is Associated with a Poor Prognosis in Patients with PDAC
Current Molecular Medicine The History of the HSV Amplicon: From Naturally Occurring Defective Genomes to Engineered Amplicon Vectors
Current Gene Therapy Targeting the Cancer Stem Cells in Endocrine Cancers with Phytochemicals
Current Topics in Medicinal Chemistry Neddylation Pathway as a Novel Anti-cancer Target: Mechanistic Investigation and Therapeutic Implication
Anti-Cancer Agents in Medicinal Chemistry VDAC1 as a Player in Mitochondria-Mediated Apoptosis and Target for Modulating Apoptosis
Current Medicinal Chemistry Versatile Applications of microRNA in Anti-Cancer Drug Discovery: From Therapeutics to Biomarkers
Current Drug Discovery Technologies Bortezomib: A New Pro-Apoptotic Agent in Cancer Treatment
Current Cancer Drug Targets The University of New Mexico Center for Molecular Discovery
Combinatorial Chemistry & High Throughput Screening Clinical Trial Update and Novel Therapeutic Approaches for Metastatic Prostate Cancer
Current Medicinal Chemistry The Role of Chronic Periodontitis in Prevention and Treatment of Head and Neck Cancers
Current Cancer Therapy Reviews Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Treatment of Nasopharyngeal Carcinoma: Therapeutic Management and Future View of Epstein-Barr Virus-Targeting Treatment
Current Cancer Therapy Reviews Non-Alkaloidal Compounds from Tubers of <i>Gloriosa superba</i> and their <i>In vitro</i> and <i>In silico</i> Antibacterial and Antioxidant Activities
Current Bioactive Compounds Autophagy Modulators and Neuroinflammation
Current Medicinal Chemistry